
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6983869/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	The â€~Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends in Biochemical Sciences, 2003, 28, 284-293.	7.5	1,093
2	Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell, 1995, 80, 729-738.	28.9	952
3	STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature, 2003, 421, 856-859.	27.8	914
4	Protein tyrosine phosphatases in signal transduction. Current Opinion in Cell Biology, 1997, 9, 193-204.	5.4	749
5	Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nature Genetics, 2007, 39, 70-74.	21.4	534
6	From Form to Function: Signaling by Protein Tyrosine Phosphatases. Cell, 1996, 87, 365-368.	28.9	529
7	Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell, 2017, 170, 1079-1095.e20.	28.9	522
8	Activating Mutations of the Noonan Syndrome-Associated <i>SHP2/PTPN11</i> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia. Cancer Research, 2004, 64, 8816-8820.	0.9	472
9	Combinatorial control of the specificity of protein tyrosine phosphatases. Current Opinion in Cell Biology, 2001, 13, 182-195.	5.4	470
10	Mathematical Models of Protein Kinase Signal Transduction. Molecular Cell, 2002, 9, 957-970.	9.7	461
11	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell, 2016, 164, 293-309.	28.9	399
12	Shp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by Controlling Csk Recruitment. Molecular Cell, 2004, 13, 341-355.	9.7	395
13	Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation. Nature Medicine, 2004, 10, 849-857.	30.7	384
14	The â€~Gab' in signal transduction. Trends in Cell Biology, 2003, 13, 122-130.	7.9	354
15	The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer and Metastasis Reviews, 2008, 27, 179-192.	5.9	343
16	Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell, 2002, 1, 479-492.	16.8	327
17	The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early xenopus development. Cell, 1995, 80, 473-483.	28.9	326
18	Leptin and Insulin Act on POMC Neurons to Promote the Browning of White Fat. Cell, 2015, 160, 88-104.	28.9	308

#	Article	IF	CITATIONS
19	Divergent Roles of SHP-2 in ERK Activation by Leptin Receptors. Journal of Biological Chemistry, 2001, 276, 4747-4755.	3.4	304
20	Cloning of p97/Gab2, the Major SHP2-Binding Protein in Hematopoietic Cells, Reveals a Novel Pathway for Cytokine-Induced Gene Activation. Molecular Cell, 1998, 2, 729-740.	9.7	296
21	Essential role for Gab2 in the allergic response. Nature, 2001, 412, 186-190.	27.8	289
22	Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure, 1998, 6, 249-254.	3.3	283
23	Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells. Cancer Discovery, 2012, 2, 172-189.	9.4	276
24	PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects. Journal of Biological Chemistry, 2006, 281, 6785-6792.	3.4	272
25	Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nature Genetics, 2000, 24, 296-299.	21.4	268
26	Diverse Biochemical Properties of Shp2 Mutants. Journal of Biological Chemistry, 2005, 280, 30984-30993.	3.4	256
27	Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell, 2005, 7, 179-191.	16.8	252
28	The role of Shp2 (PTPN11) in cancer. Current Opinion in Genetics and Development, 2007, 17, 23-30.	3.3	246
29	New Role for Shc in Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway. Molecular and Cellular Biology, 2000, 20, 7109-7120.	2.3	241
30	Receptor-Specific Regulation of Phosphatidylinositol 3′-Kinase Activation by the Protein Tyrosine Phosphatase Shp2. Molecular and Cellular Biology, 2002, 22, 4062-4072.	2.3	234
31	B Cell-Specific Deletion of Protein-Tyrosine Phosphatase Shp1 Promotes B-1a Cell Development and Causes Systemic Autoimmunity. Immunity, 2007, 27, 35-48.	14.3	231
32	Regulation of Receptor Tyrosine Kinase Signaling by Protein Tyrosine Phosphatase-1B. Journal of Biological Chemistry, 2003, 278, 739-744.	3.4	226
33	An Shp2/SFK/Ras/Erk Signaling Pathway Controls Trophoblast Stem Cell Survival. Developmental Cell, 2006, 10, 317-327.	7.0	222
34	Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome–associated PTPN11 mutation. Journal of Clinical Investigation, 2011, 121, 1026-1043.	8.2	219
35	SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discovery, 2018, 8, 1237-1249.	9.4	216
36	Regulation of Early Events in Integrin Signaling by Protein Tyrosine Phosphatase SHP-2. Molecular and Cellular Biology, 1999, 19, 3205-3215.	2.3	204

#	Article	IF	CITATIONS
37	Intramolecular Regulation of Protein Tyrosine Phosphatase SH-PTP1: A New Function for Src Homology 2 Domains. Biochemistry, 1994, 33, 15483-15493.	2.5	202
38	SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130. Journal of Biological Chemistry, 2003, 278, 661-671.	3.4	201
39	A role for the scaffolding adapter GAB2 in breast cancer. Nature Medicine, 2006, 12, 114-121.	30.7	198
40	Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6625-6630.	7.1	191
41	Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature, 2013, 499, 491-495.	27.8	190
42	Identification of Major Binding Proteins and Substrates for the SH2-Containing Protein Tyrosine Phosphatase SHP-1 in Macrophages. Molecular and Cellular Biology, 1998, 18, 3838-3850.	2.3	189
43	Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6468-6473.	7.1	188
44	Tyrosyl Phosphorylation of Shp2 Is Required for Normal ERK Activation in Response to Some, but Not All, Growth Factors. Journal of Biological Chemistry, 2003, 278, 41677-41684.	3.4	186
45	MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation. Journal of Clinical Investigation, 2011, 121, 1009-1025.	8.2	184
46	Stops along the RAS pathway in human genetic disease. Nature Medicine, 2006, 12, 283-285.	30.7	181
47	Nonreceptor Protein-Tyrosine Phosphatases in Immune Cell Signaling. Annual Review of Immunology, 2007, 25, 473-523.	21.8	174
48	Next-generation sequencing identifies rare variants associated with Noonan syndrome. Proceedings of the United States of America, 2014, 111, 11473-11478.	7.1	158
49	Role of phosphatases in lymphocyte activation. Current Opinion in Immunology, 1997, 9, 405-420.	5.5	157
50	Global Proteomic Assessment of the Classical Protein-Tyrosine Phosphatome and "Redoxome― Cell, 2011, 146, 826-840.	28.9	156
51	Vitamin C in Stem Cell Reprogramming and Cancer. Trends in Cell Biology, 2018, 28, 698-708.	7.9	139
52	SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. Journal of Experimental Medicine, 2021, 218, .	8.5	138
53	Genetic analysis of protein tyrosine phosphatases. Current Opinion in Genetics and Development, 1998, 8, 112-126.	3.3	132
54	Control of CNS Cell-Fate Decisions by SHP-2 and Its Dysregulation in Noonan Syndrome. Neuron, 2007, 54, 245-262.	8.1	128

#	Article	IF	CITATIONS
55	The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Current Biology, 1998, 8, 1009-1017.	3.9	125
56	Structural Determinants of SHP-2 Function and Specificity in <i>Xenopus</i> Mesoderm Induction. Molecular and Cellular Biology, 1998, 18, 161-177.	2.3	125
57	SHP1 Phosphatase-Dependent T Cell Inhibition by CEACAM1 Adhesion Molecule Isoforms. Immunity, 2006, 25, 769-781.	14.3	123
58	A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome. Molecular Cell, 2017, 65, 347-360.	9.7	123
59	Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome. Nature Neuroscience, 2014, 17, 1736-1743.	14.8	120
60	Structure and function of SH2-domain containing tyrosine phosphatases. Seminars in Cell Biology, 1993, 4, 419-432.	3.4	112
61	Activated Mutants of SHP-2 Preferentially Induce Elongation of <i>Xenopus</i> Animal Caps. Molecular and Cellular Biology, 2000, 20, 299-311.	2.3	112
62	Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood, 2009, 113, 4414-4424.	1.4	107
63	SHPS-1 is a scaffold for assembling distinct adhesion-regulated multi-protein complexes in macrophages. Current Biology, 1999, 9, 927-S4.	3.9	103
64	Noonan syndrome cardiac defects are caused by <i>PTPN11</i> acting in endocardium to enhance endocardial-mesenchymal transformation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4736-4741.	7.1	103
65	SHP2 Tyrosine Phosphatase Converts Parafibromin/Cdc73 from a Tumor Suppressor to an Oncogenic Driver. Molecular Cell, 2011, 43, 45-56.	9.7	97
66	Phosphatase-Dependent and -Independent Functions of Shp2 in Neural Crest Cells Underlie LEOPARD Syndrome Pathogenesis. Developmental Cell, 2010, 18, 750-762.	7.0	96
67	PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia. Nature Cell Biology, 2016, 18, 803-813.	10.3	95
68	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in <i>EGFR</i> -Mutant Lung Adenocarcinoma. Journal of Clinical Oncology, 2015, 33, 2472-2480.	1.6	94
69	CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity. Nature Immunology, 2004, 5, 651-657.	14.5	90
70	The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene, 2002, 21, 5175-5181.	5.9	88
71	Site-Selective Regulation of Platelet-Derived Growth Factor \hat{I}^2 Receptor Tyrosine Phosphorylation by T-Cell Protein Tyrosine Phosphatase. Molecular and Cellular Biology, 2004, 24, 2190-2201.	2.3	87
72	Substrate Specificity of Protein Tyrosine Phosphatases 1B, RPTPα, SHP-1, and SHP-2. Biochemistry, 2011, 50, 2339-2356.	2.5	87

#	Article	IF	CITATIONS
73	Hepatic Oxidative Stress Promotes Insulin-STAT-5 Signaling and Obesity by Inactivating Protein Tyrosine Phosphatase N2. Cell Metabolism, 2014, 20, 85-102.	16.2	83
74	SHP-1 negatively regulates neuronal survival by functioning as a TrkA phosphatase. Journal of Cell Biology, 2003, 163, 999-1010.	5.2	82
75	Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood, 2011, 117, 4253-4261.	1.4	82
76	Deletion of <i>Ptpn11</i> (Shp2) in Cardiomyocytes Causes Dilated Cardiomyopathy via Effects on the Extracellular Signal–Regulated Kinase/Mitogen-Activated Protein Kinase and RhoA Signaling Pathways. Circulation, 2008, 117, 1423-1435.	1.6	79
77	Scaffolding Adapter Grb2-Associated Binder 2 Requires Syk to Transmit Signals from FcεRI. Journal of Immunology, 2006, 176, 2421-2429.	0.8	78
78	Characterization of Two SHP-2-associated Binding Proteins and Potential Substrates in Hematopoietic Cells. Journal of Biological Chemistry, 1997, 272, 16421-16430.	3.4	76
79	The RhoGEF GEF-H1 Is Required for Oncogenic RAS Signaling via KSR-1. Cancer Cell, 2014, 25, 181-195.	16.8	76
80	The Scaffolding Adapter Gab2, via Shp-2, Regulates Kit-evoked Mast Cell Proliferation by Activating the Rac/JNK Pathway. Journal of Biological Chemistry, 2006, 281, 28615-28626.	3.4	75
81	The Docking Molecule Gab2 Is Induced by Lymphocyte Activation and Is Involved in Signaling by Interleukin-2 and Interleukin-15 but Not Other Common γ Chain-using Cytokines. Journal of Biological Chemistry, 2000, 275, 26959-26966.	3.4	75
82	Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function. Blood, 2013, 121, 4205-4220.	1.4	74
83	The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. International Immunology, 1999, 11, 1999-2014.	4.0	73
84	Sticking It to Cancer with Molecular Glue for SHP2. Cancer Cell, 2016, 30, 194-196.	16.8	72
85	Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E468-E477.	7.1	72
86	Cutting Edge: Gab2 Mediates an Inhibitory Phosphatidylinositol 3′-Kinase Pathway in T Cell Antigen Receptor Signaling. Journal of Immunology, 2000, 165, 4158-4163.	0.8	68
87	Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome. Human Mutation, 2015, 36, 1080-1087.	2.5	67
88	Protein-tyrosine Phosphatase SHP-1 Is Dispensable for FcÎ ³ RIIB-mediated Inhibition of B Cell Antigen Receptor Activation. Journal of Biological Chemistry, 1997, 272, 20038-20043.	3.4	66
89	Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. Cancer Discovery, 2021, 11, 384-407.	9.4	64
90	Regulation of B cell signal transduction by SH2-containing protein–tyrosine phosphatases. Seminars in Immunology, 1998, 10, 329-347.	5.6	62

#	Article	IF	CITATIONS
91	A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood, 2010, 116, 3611-3621.	1.4	60
92	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. Cancer Discovery, 2022, 12, 47-61.	9.4	58
93	Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor–Activating Mutations. Cancer Research, 2010, 70, 3843-3850.	0.9	55
94	Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). BMC Structural Biology, 2014, 14, 10.	2.3	55
95	Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21. Journal of Experimental Medicine, 2020, 217, .	8.5	51
96	Inhibition of IFN-Â signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10267-10272.	7.1	50
97	SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. Journal of Cell Biology, 2006, 175, 87-97.	5.2	50
98	The Protein Tyrosine Phosphatase Receptor Delta Regulates Developmental Neurogenesis. Cell Reports, 2020, 30, 215-228.e5.	6.4	50
99	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. Cancer Discovery, 2021, 11, 362-383.	9.4	50
100	Phosphorylation of Protein-tyrosine Phosphatase PTP-1B on Identical Sites Suggests Activation of a Common Signaling Pathway during Mitosis and Stress Response in Mammalian Cells. Journal of Biological Chemistry, 1997, 272, 2957-2962.	3.4	46
101	Altered Glucose Homeostasis in Mice with Liver-specific Deletion of Src Homology Phosphatase 2. Journal of Biological Chemistry, 2010, 285, 39750-39758.	3.4	46
102	Offâ€ŧarget inhibition by active siteâ€ŧargeting <scp>SHP</scp> 2 inhibitors. FEBS Open Bio, 2018, 8, 1405-1411.	2.3	44
103	Assay to visualize specific protein oxidation reveals spatio-temporal regulation of SHP2. Nature Communications, 2017, 8, 466.	12.8	43
104	Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer. Cancer Discovery, 2022, 12, 1022-1045.	9.4	43
105	Resveratrol Inhibits Angiotensin II- and Epidermal Growth Factor-Mediated Akt Activation: Role of Gab1 and Shp2. Molecular Pharmacology, 2005, 68, 41-48.	2.3	42
106	Gain-of-function mutations of <i>Ptpn11</i> (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 984-989.	7.1	41
107	Genetic and cellular mechanisms of oncogenesis. Current Opinion in Genetics and Development, 2007, 17, 1-2.	3.3	40
108	<i>SOS1</i> mutations are rare in human malignancies: Implications for Noonan syndrome patients. Genes Chromosomes and Cancer, 2008, 47, 253-259.	2.8	40

#	Article	IF	CITATIONS
109	Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia. Cancer Research, 2018, 78, 75-87.	0.9	39
110	Methods to monitor classical proteinâ€ŧyrosine phosphatase oxidation. FEBS Journal, 2013, 280, 459-475.	4.7	38
111	Antagonism between binding site affinity and conformational dynamics tunes alternative cis-interactions within Shp2. Nature Communications, 2013, 4, 2037.	12.8	38
112	Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. Cell Reports, 2017, 18, 2343-2358.	6.4	38
113	Receptor-Type Protein-Tyrosine Phosphatase μ Is Expressed in Specific Vascular Endothelial Bedsin Vivo. Experimental Cell Research, 1999, 248, 329-338.	2.6	36
114	Increased BRAF Heterodimerization Is the Common Pathogenic Mechanism for Noonan Syndrome-Associated <i>RAF1</i> Mutants. Molecular and Cellular Biology, 2012, 32, 3872-3890.	2.3	35
115	Hepatocyte-Specific <i>Ptpn6</i> Deletion Protects From Obesity-Linked Hepatic Insulin Resistance. Diabetes, 2012, 61, 1949-1958.	0.6	34
116	Tyrosine phosphatase SHP-2 is a mediator of activity-dependent neuronal excitotoxicity. EMBO Journal, 2005, 24, 305-314.	7.8	33
117	The Signaling Adaptor Gab1 Regulates Cell Polarity by Acting as a PAR Protein Scaffold. Molecular Cell, 2012, 47, 469-483.	9.7	33
118	SHP2 regulates skeletal cell fate by modifying SOX9 expression and transcriptional activity. Bone Research, 2018, 6, 12.	11.4	33
119	A ERK/RSKâ€mediated negative feedback loop regulates M SF–evoked PI3K/AKT activation in macrophages. FASEB Journal, 2018, 32, 875-887.	0.5	31
120	N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer. Cell Systems, 2019, 8, 345-351.e4.	6.2	31
121	Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation. Cell Reports, 2017, 18, 2932-2942.	6.4	28
122	Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner. Science Signaling, 2018, 11, .	3.6	27
123	SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations. Science Translational Medicine, 2021, 13, .	12.4	26
124	Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. Journal of Experimental Medicine, 2016, 213, 25-34.	8.5	25
125	Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase ε. Molecular Cell, 2020, 80, 682-698.e7.	9.7	25
126	Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood, 2016, 127, 1803-1813.	1.4	24

#	Article	IF	CITATIONS
127	Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome. Nature Communications, 2017, 8, 15518.	12.8	23
128	A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. American Journal of Pathology, 2018, 188, 1120-1131.	3.8	23
129	Piecing Together a Broken Tumor Suppressor Phosphatase for Cancer Therapy. Cell, 2020, 181, 514-517.	28.9	23
130	The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning. PLoS Genetics, 2019, 15, e1008108.	3.5	22
131	An eye on organ development. Nature, 2003, 426, 238-239.	27.8	18
132	Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions. Journal of Biological Chemistry, 2020, 295, 18036-18050.	3.4	16
133	SH2 Domain-Containing Protein-Tyrosine Phosphatases. , 2010, , 771-809.		14
134	Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1). Journal of Biological Chemistry, 2016, 291, 15641-15652.	3.4	14
135	Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Research, 2018, 78, 6539-6548.	0.9	12
136	Role of PTPN11 (SHP2) in Cancer. , 2016, , 115-143.		11
137	Identification of a Domain in the β Subunit of the Type I Interferon (IFN) Receptor That Exhibits a Negative Regulatory Effect in the Growth Inhibitory Action of Type I IFNs. Journal of Biological Chemistry, 1998, 273, 5577-5581.	3.4	10
138	From an orphan disease to a generalized molecular mechanism. Rare Diseases (Austin, Tex), 2013, 1, e26657.	1.8	10
139	Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	10
140	Leukemogenic Ptpn11 Allele Causes Defective Erythropoiesis in Mice. PLoS ONE, 2014, 9, e109682.	2.5	8
141	SH2-Domain-Containing Protein–Tyrosine Phosphatases. , 2003, , 707-728.		7
142	MMD-associated <i>RNF213</i> SNPs encode dominant-negative alleles that globally impair ubiquitylation. Life Science Alliance, 2022, 5, e202000807.	2.8	7
143	Tyrosyl phosphorylation toggles a Runx1 switch. Genes and Development, 2012, 26, 1520-1526.	5.9	4
144	Signal transfer in human protein tyrosine phosphatase PTP1B from allosteric inhibitor P00058. Journal of Biomolecular Structure and Dynamics, 2022, 40, 13823-13832.	3.5	4

#	Article	IF	CITATIONS
145	Activated Thiol Sepharoseâ€based proteomic approach to quantify reversible protein oxidation. FASEB Journal, 2019, 33, 12336-12347.	0.5	3
146	U.S. Biomedical Research Needs More Immigrant Scientists, Not Fewer!. Cancer Cell, 2020, 38, 308.	16.8	2
147	Hidesaburo Hanafusa 1929–2009. Cell, 2009, 137, 197-199.	28.9	1
148	Hidesaburo Hanafusa 1929–2009. Molecular Cell, 2009, 34, 141-143.	9.7	0
149	New pROSpects for PTP1B: micro-Managing Oncogene-Induced Senescence. Molecular Cell, 2014, 55, 651-653.	9.7	Ο
150	Redox Regulation of PTPs in Metabolism: Focus on Assays. , 2013, , 1-26.		0
151	Raymond L. Erikson (1936–2020). Cell, 2020, 181, 961-963.	28.9	0